Kings Path Partners LLC Raises Holdings in Phibro Animal Health Corporation $PAHC

Key Points

• Kings Path Partners LLC increased its stake in Phibro Animal Health Corporation by 87.3%, owning 20,600 shares valued at approximately $526,000.
• Phibro Animal Health reported an earnings per share (EPS) of $0.57 for the last quarter, exceeding analysts' expectations of $0.52.
• The company announced a quarterly dividend of $0.12 per share, representing an annualized yield of 1.2% and a payout ratio of 40.68%.

Kings Path Partners LLC boosted its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 87.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,600 shares of the company's stock after purchasing an additional 9,600 shares during the quarter. Kings Path Partners LLC owned approximately 0.05% of Phibro Animal Health worth $526,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Phibro Animal Health during the 4th quarter worth about $29,000. National Bank of Canada FI purchased a new position in shares of Phibro Animal Health in the 1st quarter valued at about $30,000. Lazard Asset Management LLC increased its holdings in shares of Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after acquiring an additional 1,589 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Phibro Animal Health in the 4th quarter valued at about $69,000. Finally, Curat Global LLC purchased a new position in shares of Phibro Animal Health in the 1st quarter valued at about $146,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 3,520 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $41.29, for a total transaction of $145,340.80. Following the completion of the sale, the chief executive officer directly owned 41,880 shares of the company's stock, valued at approximately $1,729,225.20. This trade represents a 7.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 50.07% of the company's stock.

Phibro Animal Health Trading Down 3.8%

NASDAQ:PAHC opened at $39.62 on Friday. The stock's 50 day moving average price is $31.98 and its 200 day moving average price is $25.53. The company has a market capitalization of $1.61 billion, a PE ratio of 33.58, a P/E/G ratio of 1.22 and a beta of 0.89. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $41.57.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. The firm had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is presently 40.68%.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of recent analyst reports. Zacks Research downgraded Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 28th. Bank of America increased their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a report on Friday, August 29th. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective on the stock in a report on Monday, June 16th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a report on Thursday, August 28th. Finally, JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $25.00 to $35.00 in a report on Monday, July 7th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, Phibro Animal Health presently has an average rating of "Reduce" and a consensus target price of $28.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.